{"prompt": "['completed instead. Parents or caregivers of adolescents will also complete an Informed Consent Form. The enrollment form will be completed after informed', 'consent and/or assent is obtained. All screening evaluations must be completed and reviewed to confirm that patients meet all eligibility criteria', 'before', 'enrollment.', 'd. Medical history and demographics dData will be collected from patient medical records and documented in the eCRF. Medical history includes hemophilia-', 'related history, clinically significant diseases, procedures (including prior surgeries), use of alcohol and drugs of abuse within the past year, and medication allergies. In', 'particular, sites should record whether the patient has any history of prior ITI, anaphylaxis, or known thrombophilia. It should also include all medication', 'taken', 'in', 'the', '4 weeks prior to screening (including prescription drugs, over-the-counter drugs, and herbal/nomeopathic remedies and therapies). Any hemostatic medications (e.g.', 'bypassing agents) and other medications used to treat or prevent bleeds in the 6-month period prior to starting emicizumab treatment will also be collected. Demographic', 'data will include age, sex, and self-reported race and ethnicity.', 'e. A complete physical examination will be performed at-during Screening and should include, but not necessarily be limited to, an evaluation of the head, eyes,', 'ears, nose, and throat and the cardiovascular, dermatological, musculoskeletal, respiratory, gastrointestinal and neurological systems. Any abnormality identified during', 'screening should be recorded on the General Medical History and Baseline Conditions eCRF. and targeted physical examinations will be performed at the visits', 'indicated.-Targeted physical examinations (i.e., of-joints (for bleeds, evidence of arthropathy; ) and skin (for bruises, hematomas, and injection site', 'reactionsISRs; ), addition to other organ systems as clinically indicated), should be conducted at subsequent visits or performed as clinically indicated. New', 'or worsened clinically significant abnormalities from screening should be recorded as adverse events, if appropriate, on the Adverse Event eCRF.', 'f. Vital signs include measurement of body temperature (oral, rectal, axillary, or tympanic), heart and respiratory rates, blood pressure, pulse, respiratory rate,', 'and weight-will be measured. On treatment days, measurement should occur at each clinic to any emicizumab administration-injection, if applicable.', 'Height will be measured and recorded only during at Screening and 6 and 12 months after starting emicizumab. Additional vital signs assessments may also', \"be taken anytime as unscheduled assessments as judged by the investigator. In addition, At the investigator's discretion, vital signs may be taken to help monitor\", \"for hypersensitivity reactions during or after injections at the investigator's discretion,, although these data but they-should not be entered into the eCRF.\", 'g.', 'Patients will be asked about concomitant medications (e.g., extra pain edication following a bleed) at each', 'clinic', 'visit', 'indicated,', 'with', 'the', 'exception', 'treatments', 'for', 'bleeds', '(i.o.', 'bypassing', 'agents', 'and', 'other', 'medications', 'to', 'treat', 'bleeds),', 'which', 'will', 'be', 'collected', 'in', 'the', 'bleed', 'records', 'Any', 'hemostatic', 'medications used to treat or prevent bleeds in the week prior to starting emicizumab treatment will also be collected. The definition of concomitant', 'medications, as well as permitted and prohibited medications is described in Section 4.4. Concomitant medications used by a patient from 4 weeks prior to initiation of', 'emicizumab to the Study Completion/Early Termination Visit (or to the Safety Follow-up Visit, if applicable) should be reported to the investigator', 'and', 'recorded', 'on', 'the', 'Concomitant Medications eCRF. Treatments for bleeds (i.e., bypassing agents and other medications to treat bleeds), will be collected in the bleed records.', 'h. Hematology and blood chemistry Laboratory assessments will include a complete blood count with differential and serum chemistries (see Section 4.5.6.1).', 'Safety -Llaboratory assessments completed at-during Screening do not have to be repeated at Week 1, if the period between Screening and Week 1 is <', \"5 days and there has been no change in the patient's health status as assessed by the investigator. Laboratory assessments will be analysed at central\", \"aboratory.Additional analysis will be performed at a local laboratory, as per the investigator's discretion. Samples will be sent to the central laboratory for\", 'analysis.', 'i.', 'Pregnancy tests: Female patients of childbearing potential (including those who have had a tubal ligation) will be required to have a negative serum', 'pregnancy test result at-during Screening (and again within 7 days prior to the first dose of emicizumab). and-Uurine pregnancy tests will be performed', 'throughout the study treatment period. at every clinic visit, with the exception of Weeks 2 and 3. Pregnancy testing will be conductedanalysed at the local', 'laboratory.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '51 / Protocol MO39129, Version 3']['j.', 'HIV and hepatitis-serology will be conducted at Screening at the local laboratory.The specific tests utilized for hepatitis and HIV serology testing are per', 'local standard of care. As this patient population is at high risk for HIV, hepatitis A, B and C, sites should consider testing for these. While the specific serological tests', \"used is at the discretion of the Investigator, this is with the understanding that the status of that participants' hepatitis or HIV is confidently known at time at\", 'enrollment. HIV and hepatitis serology tests will be conducted at the local laboratory.', 'k. For the assessment of anti-FVIII antibodies (inhibitors), functional assays that utilize a clotting readout (classic Bethesda or Nijmegen assay) cannot be used for', 'patients on emicizumab therapy as emicizumab drives clotting even in the presence of FVIII inhibitors, causing a false-negative test result (see Section 5.1.3). After the', 'first dose, local measurement of FVIII inhibitors, if indicated, requires use of an ELISA-based test or a chromogenic Bethesda assay. anti FVIII antibodies (FVIII', 'inhibitor titer) will be analysed at Screening and at the visits indicated. Anti FVIII antibody assessments will be conducted at a central laboratory.', \"Additional analysis will be performed at a local laboratory, as per the investigator's discretion. At the discretion of the local investigator, any additional urgent\", 'request to assess FVIII inhibitors will need to be sent to the central laboratory (see Appendix 2 for additional information). Plasma samples for anti-FVIII antibodies will', 'be analysed at the central laboratory', 'I.', 'Plasma samples are required for immunogenicity assessments to detect anti-emicizumab antibodies-will be. collected at screening and prior to emicizumab', 'administration at the visits indicated. Additional samples to detect anti-emicizumab antibodies may also be drawn at the time of hypersensitivity events or', 'following suspected loss of efficacy. nti emicizumab antibody assessments will be conducted-Sample will be analysed at the-a central laboratory.', 'Additional analysis will be performed at a local laboratory as per the investigator discretion', 'm. ePRO bleed / medication recording: At the Week 1 visit, patients will be trained on how to record their bleeds and hemophilia medication use on the ePRO', 'device where possible. Data that need to be recorded will include the site of bleed, type of bleed, time of each individual bleed (day, start and stop time), and', 'treatment for bleed. At least once a week, patients will need to record any hemophilia medication use (including emicizumab) and information regarding any bleeding', 'events. Patients will record when they have bleeds or hemophilia medication use, including emicizumab or at least every week. Investigator review of', 'patient-reported bleed/medication records with the patient/caregiver will occur for completeness and accuracy at all of the visits during the treatment', 'period, at study completion, at any unscheduled visits (if required), and at the Early Termination Visit (if required).', 'n. Thorough documentation on surgical events will be requested, including type of surgery or procedures, treatments, outcomes, etc.', 'o. Adverse events: After informed consent has been obtained but prior to initiation of emicizumab, only serious adverse events caused by a protocol-mandated', 'intervention should be reported. Injection-site reaction adverse events will be collected on a-the injection site reaction form. separate form from the adverse', 'event form.', 'p. Management of emicizumab: Drug dispensation will not occur at the Study Completion Visit or the Early Termination Visit (if required). Patients will only', 'receive emicizumab IMP during an unscheduled visit if drug dispensation is required at this time.', 'q.', 'HRQoL and EQ-5D-5L: Prior to the first emicizumab administration: at the 3, 6, 12, and 18 month assessments; and at study completion (2 years),', 'Ppatients will be compted-requested to complete Haem-A-QoL (adults age: 18 years) or the Haemo-QoL-SF (adolescents ages: 12-17 years)', 'questionnaire and the EQ-5D-5L questionnaire. Questionnaires will be self-administered electronically before the patient/caregiver receives any information on', 'disease status, prior to the performance of non-PRO assessments, and prior to emicizumab administration (if on a treatment day). Paper versions of the questionnaires', 'are also available in case of ePRO outage or if an ePRO device is otherwise unavailable.', 'r.', 'EmiPref: At the 3-month assessment, patients will be prompted to complete a paper version of the EmiPref questionnaire (Appendix 3). The questionnaire will', 'be self-administered before the patient/caregiver receives any information on disease status, prior to the performance of non-PRO assessments, and prior to emicizumab', 'administration (if on a treatment day).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '52 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}